deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT02116777

Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies

A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies

Sponsor: National Cancer Institute (NCI)

Conditions Adult Solid Neoplasm Childhood Solid Neoplasm Recurrent Childhood Central Nervous System Neoplasm Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Recurrent Malignant Solid Neoplasm Refractory Central Nervous System Neoplasm
Interventions Laboratory Biomarker Analysis Pharmacological Study Talazoparib Temozolomide
Updated 18 times since 2017 Last updated: Mar 1, 2021 Started: May 16, 2014 Primary completion: Dec 31, 2018 Completion: Dec 31, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Adult Solid Neoplasm and Childhood Solid Neoplasm, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 18 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Dec 2017 · 6 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Dec 2018 · 4 months · monthly snapshot~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Oct 2019 · 6 months · monthly snapshot~Oct 2019 – ~Jan 2021 · 15 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Jul 2024 · 39 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Apr 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  5. Jan 2021 — Apr 2021 [monthly]

    Completed PHASE1_PHASE2

▶ Show 13 earlier versions

  1. Oct 2019 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  2. Apr 2019 — Oct 2019 [monthly]

    Completed PHASE1_PHASE2

  3. Mar 2019 — Apr 2019 [monthly]

    Completed PHASE1_PHASE2

  4. Feb 2019 — Mar 2019 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  5. Dec 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Aug 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Jul 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Suspended → Active Not Recruiting

  8. Jun 2018 — Jul 2018 [monthly]

    Suspended PHASE1_PHASE2

  9. Dec 2017 — Jun 2018 [monthly]

    Suspended PHASE1_PHASE2

    Status: Recruiting → Suspended

  10. Jun 2017 — Dec 2017 [monthly]

    Recruiting PHASE1_PHASE2

  11. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE1_PHASE2

  12. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE1_PHASE2

  13. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

May 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Atlanta, United States , Aurora, United States , Birmingham, United States , Chicago, United States , Cincinnati, United States , Houston, United States , Indianapolis, United States , Los Angeles, United States , Memphis, United States and 11 more locations